Table 2.
Comparison of laboratory parameters among the three groups of COVID-19 patients.
| Median (IQR) | ||||||
|---|---|---|---|---|---|---|
| Normal range | Total (n = 132) | Group A (n = 41) | Group B (n = 44) | Group C (n = 47) | P-value | |
| HbA1c (%) | 4.0–6.0 | 6.4 (5.8–7.2) | 5.7 (5.4–5.8) | 6.4 (6.2–6.5) | 7.5 (7.1–8.7) | <0.01 |
| Fbg (g/L) | 2.0–4.0 | 5.3 (4.3–6.8) | 4.6 (3.8–5.7) | 5.4 (4.4–7.0) | 5.8(4.7–7.3) | <0.01 |
| Leukocytes (×109/L) | 3.5–9.5 | 4.9 (4.1–6.0) | 4.6 (3.9–5.3) | 5.0 (4.2–6.4) | 5.3 (4.1–6.8) | 0.12 |
| Lymphocytes (×109/L) | 1.1–3.2 | 0.8 (0.5–1.3) | 0.8 (0.6–1.5) | 0.8 (0.5–1.4) | 0.8 (0.5–1.2) | 0.68 |
| Serum ferritin (µg/L) | 30.0–400.0 | 668.3 (349.7–1488.3) | 372.8 (226–1064.9) | 734.3 (354.8–1502.9) | 1255.0 (564.3–2110.1) | <0.01 |
| LDH (U/L) | 135.0–225.0 | 289.0 (241.0–431.3) | 276.0 (226.0–319.0) | 325.0 (263.5–451.0) | 276.0 (239.0–473.0) | 0.64 |
| CRP (mg/L) | <1.0 | 38.3 (5.3–107.8) | 17.3 (2.9–61.7) | 41.6 (5.2–109.7) | 57.9 (11.0–185.6) | <0.01 |
| IL-1β (pg/mL) | <5.0 | 5.0 (5.0–5.0) | 5.0 (5.0–5.0) | 5.0 (5.0–5.0) | 5.0 (5.0–5.8) | 0.09 |
| IL-2 (U/mL) | 223.0–710.0 | 657 (416.1–1146) | 565.0 (378.5–974.0) | 739.5 (407.1–1164.8) | 808.0 (501.0–1336.0) | 0.09 |
| IL-6 (pg/mL) | <7.0 | 14.9 (4.0–56) | 12.7 (3.5–40.5) | 9.6 (3.2–64.5) | 29.6 (8.5–90.7) | 0.04 |
| IL-8 (pg/mL) | <62.0 | 16.1 (7.8–29.3) | 12.1 (7–17.0) | 18.5 (9.1–31.9) | 21.0 (7.3–43.2) | 0.15 |
| IL-10 (pg/mL) | <9.1 | 5.0 (5.0–7.5) | 5.0 (5.0–6.9) | 5.0 (5.0–6.9) | 21.0 (7.3–43.2) | 0.11 |
| TNF-α (pg/mL) | <8.1 | 9.2 (5.9–14.0) | 8.4 (5.3–13.9) | 8.7 (5.9–12.8) | 11.0 (6.9–15.9) | 0.17 |
| ESR (mm/h) | 0.0–15.0 | 37.0 (18–64) | 22.0 (9.0–53.0) | 39.5 (24.3–63.3) | 46.0 (20.0–82.3) | <0.01 |
| TG (mmol/L) | <1.7 | 1.5 (1.1–2.1) | 1.3 (1.0–1.9) | 1.2 (1.0–1.9) | 1.8 (1.3–2.3) | 0.08 |